In observance of Rare Disease Day, it is imperative to underscore the progressive strides within the domain of rare disease research. Rare diseases, characterized by their infrequent occurrence within the general populace, impose significant burdens not only on the affected … Read More
Breaking News
Reassessing Approaches and Attitudes to Medication Adherence in Drug Trials
It is human nature for people to trust the things that are known to them ahead of the things that are not. Familiarity, after all, brings with it a sense of comfort and reassurance. It is perhaps understandable, therefore, that … Read More
Ignorance of ALCOA+ is a Risk to Regulatory Compliance
In this article, AARDEX Group Quality Manager, Oana Paun, discusses ALCOA+ and its importance for achieving regulatory compliance. For those with a scientific ear, it can be reassuring when you hear ideas discussed in terms of data. The word alone … Read More
Is Neglecting Medication Adherence in Neurology Drug Trials Putting Patients at Risk?
The list of Neurological conditions is considerable, with epilepsy, Alzheimer’s disease, dementia, stroke, migraine, multiple sclerosis, Parkinson’s disease, neuro infections, and brain tumors, all attributed to this category of disease. Hundreds of millions of people worldwide are affected by neurological … Read More
Unmasking Bias in Clinical Research: A Historical Perspective
It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality, … Read More
Dose Optimization: Getting to the Root of a Long-Term Issue
In this article, Dr. Vrijens shares his thoughts on the need for dose optimization in the interests of balancing safety and efficacy. How we use language has a huge bearing on the meaning we convey. Take the word ‘overdose’, for … Read More
From Estimation to Calculation: Exploring the Power of Medication Adherence Data
In this article, Dr. Bernard Vrijens discusses the importance of medication adherence data in clinical trials and why medication adherence should be a calculation, not an estimation. The world is today collecting a mind-blowing amount of data. Indeed, IDC calculates that about … Read More
ROI: Understanding the True Cost of Medication Non-Adherence in Clinical Trials
In this article, our Scientific Lead, Bernard Vrijens, discusses the influence of medication non-adherence on ROI in clinical trials. Get ready for an insightful read! Fraught with risk yet pivotal to the future success of a drug candidate, clinical trials … Read More
FDA Proposes Updates to Drug Labeling Regs to Include New Patient Medication Information (PMI) Guide for Prescription Drug Products
This action, if finalized, will require applicants to create a new type of medication guide, referred to as Patient Medication Information (PMI). In this article, our Scientific Lead, Bernard Vrijens, unpacks the proposals and questions whether more is needed to … Read More
AARDEX Group Announced as Founding Member of CancerX Initiative to Drive Innovation in the Fight Against Cancer
Adherence specialists join multi-stakeholder CancerX initiative to improve long-term pathways for cancer patients and meet the challenge of oral treatments. Liege, Belgium- July 18, 2023: Adherence specialist AARDEX Group is proud to announce it is a founding member of the CancerX initiative, bringing … Read More